Suppr超能文献

急性肾损伤的腹膜透析:重回一线治疗

Peritoneal dialysis for acute kidney injury: back on the front-line.

作者信息

Cullis Brett

机构信息

University of Cape Town Nephrology and Child Health Rondebosch, Western Cape, South Africa.

Hilton Life Hospital - Renal and Intensive Care Unit, Pietermaritzburg, KZN, South Africa.

出版信息

Clin Kidney J. 2022 Sep 11;16(2):210-217. doi: 10.1093/ckj/sfac201. eCollection 2023 Feb.

Abstract

Peritoneal dialysis (PD) for acute kidney injury (AKI) has been available for nearly 80 years and has been through periods of use and disuse largely determined by availability of other modalities of kidney replacement therapy and the relative enthusiasm of clinicians. In the past 10 years there has been a resurgence in the use of acute PD globally, facilitated by promotion of PD for AKI in lower resource countries by nephrology organizations effected through the Saving Young Lives program and collaborations with the World Health Organisation, the development of guidelines standardizing prescribing practices and finally the COVID-19 pandemic. This review highlights the history of PD for AKI and looks at misconceptions about efficacy as well as the available evidence demonstrating that acute PD is a safe and lifesaving therapy with comparable outcomes to other modalities of treatment.

摘要

腹膜透析(PD)用于急性肾损伤(AKI)已有近80年历史,其应用经历了兴衰变迁,这在很大程度上取决于其他肾脏替代治疗方式的可及性以及临床医生的相对积极性。在过去10年里,全球急性腹膜透析的使用再度兴起,这得益于肾脏病学组织通过“拯救年轻生命”计划以及与世界卫生组织的合作,在资源匮乏国家推广急性肾损伤的腹膜透析治疗;得益于规范处方实践指南的制定;最终还得益于新冠疫情。本综述重点介绍了急性肾损伤腹膜透析的历史,审视了对其疗效的误解,以及现有证据表明急性腹膜透析是一种安全的救命疗法,其治疗效果与其他治疗方式相当。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/915d/9900590/623065f7da3f/sfac201fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验